Ajanta Pharma Limited has submitted its quarterly compliance certificate under SEBI (Depositories and Participants) Regulations, 2018 to stock exchanges for the quarter ended 31st March 2026. The pharmaceutical company filed the mandatory certificate on 6th April 2026, demonstrating its commitment to regulatory compliance.

Regulatory Compliance Certificate Details

The certificate was issued under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 by MUFG Intime India Private Limited, formerly known as Link Intime India Private Limited, which serves as the company's registrar and share transfer agent.

Certificate Confirmation Process

MUFG Intime India Private Limited confirmed that all securities received from depository participants for dematerialisation during the quarter were properly processed according to regulatory requirements. The registrar verified that:

• Securities received for dematerialisation were confirmed or rejected to depositories within prescribed timelines
• Security certificates comprised in dematerialisation requests have been listed on stock exchanges where existing securities are traded
• Physical security certificates received were mutilated and cancelled after proper verification
• Depository names were substituted in the register of members as registered owners

Corporate Governance and Compliance

The submission was signed by Gaurang Shah, Senior Vice President - Legal & Company Secretary of Ajanta Pharma, while the certificate was issued by Ashok Shetty, Senior Vice President-Corporate Registry at MUFG Intime India Private Limited. This quarterly filing represents part of the company's ongoing regulatory compliance obligations under SEBI guidelines for listed companies.

The certificate filing ensures transparency in the dematerialisation process and confirms that all procedural requirements have been met during the reporting quarter, maintaining investor confidence in the company's operational compliance standards.

Ajanta pharma promoter Aayush Agrawal has pledged 3,85,000 shares of the pharmaceutical company to enhance loan facilities. The pledge creation was disclosed to stock exchanges on March 31, 2026, in accordance with SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Pledge Details and Purpose

The pledge was created on March 30, 2026, by Aayush Agrawal in his capacity as trustee of Aayush Agrawal Trust. The stated reason for the pledge creation is to increase loan facilities. The pledged shares represent 0.31% of the company's total share capital.

Promoter Holdings and Encumbrance Status

Following this pledge creation, the encumbrance position of Aayush Agrawal Trust has been updated. The trust holds a total of 1,41,12,924 shares in Ajanta Pharma Limited, representing 11.30% of the total share capital.

Regulatory Compliance

The disclosure was made to both BSE and NSE on March 31, 2026, following the prescribed format under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The company secretary of Ajanta Pharma Limited was also informed about the pledge creation as part of the regulatory compliance process.

Promoter Group Holdings Overview

The disclosure document reveals the comprehensive shareholding pattern of the promoter group. Other significant promoter holdings include Yogesh Agrawal Trust with 1,80,78,147 shares (14.47%) and Rajesh Agrawal Trust with 1,80,78,148 shares (14.47%). Gabs Investments Pvt Ltd holds 1,25,88,393 shares representing 10.08% of the total share capital.

The pledge creation is part of routine corporate financing activities and demonstrates the promoter's commitment to leveraging shareholding for business expansion and financial flexibility.